Chemotherapy, in its most general sense, is the treatment of disease by chemicals especially by killing micro-organisms or cancerous cells. In popular usage, it refers to antineoplastic drugs used to treat cancer or the combination of these drugs into a cytotoxic standardized treatment regimen.
Next-generation gene sequencing (NGS) technologies --in which millions of DNA molecules are simultaneously but individually analyzed-- theoretically provides researchers and clinicians the ability to noninvasively identify mutations in the blood stream.
According to recent research at the University of Guelph, a compound found in avocados may one day lead to improved leukemia treatment.
According to a new study, targeting a pathway that is critical for the survival of some cases of acute myeloid leukemia could open up a new therapeutic route for patients.
Chemotherapy is a drug treatment that uses powerful chemicals to kill fast-growing cancer cells in the body. It is a systemic treatment where drugs travel throughout the body and destroy cancer cells that have spread (metastasized) to parts of the body far away from the original (primary) tumour.
A new study has shown that it is viable to reduce tumor growth by a therapy that involves tagging cancer cells with various therapeutic molecules.
An innovative new technique that encourages cancer cells in the kidneys to self-destruct could revolutionize the treatment of the disease, a new study in the journal Pharmaceutics reports.
A research team has revealed that neural stem cells (NSCs)—that is, the stem cells of the nervous system—age quickly.
Researchers from the National Institutes of Health have identified and tested a drug combination that exploits a weakness in small cell lung cancer (SCLC), an aggressive, dangerous cancer.
Researchers have detected and validated groups of genes linked to immunotherapy resistance in patients with metastatic urothelial cancer of the bladder.
Patients with a high number of genes most associated with pathways that lead to cell death in lung cancer are at increased risk of dying early from their disease, researchers report.
Scientists from Buck Institute have identified and are now developing an innovative, non-invasive biomarker test that could help quantify and track the performance of senolytics—a class of drugs that selectively destroy senescent cells.
A pre-clinical study for melanoma and neuroblastoma shows that a customized tumor cell vaccine technique that targets Myc oncogenes coupled with checkpoint therapy produces an active immune response that bypasses antigen selection and immune privilege.
A research team from Italy has discovered a pair of microRNA molecules that assist in maintaining a population of cancerous stem cells that fuel the growth of breast cancers and trigger tumor relapse after treatment.
Chimeric antigen receptor T-cell therapy, or CAR T, is a relatively new type of therapy approved to treat several types of aggressive B cell leukemias and lymphomas.
Scientists have genetically engineered immune cells, called myeloid cells, to precisely deliver an anticancer signal to organs where cancer may spread.
A majority of the drugs work through the membranes surrounding the cells of the body.
A team of researchers led by Professor Yaakov Nahmias, director of the Grass Center for Bioengineering at the Hebrew University of Jerusalem and founder of Tissue Dynamic, introduced a new technological approach that has the potential to rapidly develop new drugs without the need for animal experiments.
In this interview, AZoLifeSciences speaks to Professor Masaru Ishii about his latest research that investigated how bone marrow regenerates after chemotherapy.
A new substance could improve the treatment of persistent cancers. Researchers at Martin Luther University Halle-Wittenberg and the University of Greifswald have developed a new inhibitor that makes drug-resistant tumor cells respond again to chemotherapy.
Chemotherapy has a damaging effect on hematopoietic stem and progenitor cells (HSPCs) in bone marrow. However, once chemotherapy ends, HSPCs regenerate, a process that has remained unknown--until now.